3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 2
4
Phase 4
1
Phase 1/2
1
Status
Completed
3
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
4
Conditions
Colorectal Neoplasms
86
Ovarian Neoplasms
33
Breast Neoplasms
29
Carcinoma, Non-Small-Cell Lung
28
Colonic Neoplasms
23
Rectal Neoplasms
21
Fallopian Tube Neoplasms
17
Neoplasms
16
Neoplasm Metastasis
13
Carcinoma, Hepatocellular
13
Glioblastoma
11
Lung Neoplasms
10
Brain Neoplasms
8
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Intestinal Neoplasms
5
Gastrointestinal Neoplasms
5
Digestive System Neoplasms
5
Brenner Tumor
5
Recurrence
4
Peritoneal Neoplasms
4
Glioma
4
Carcinoma, Ovarian Epithelial
4
Adenocarcinoma of Lung
4
Rectal Diseases
3
Non-Squamous Non-Small Cell Lung Cancer
3
Liver Neoplasms
3
Intestinal Diseases
3
Gastrointestinal Diseases
3
Interventions
Carboplatin
8
Paclitaxel
7
Hyperthermic Intraperitoneal Chemotherapy
7
Bevacizumab
4
liposomal doxorubicin
3
Gemcitabine
3
Oxaliplatin
2
Neoadjuvant Therapy
2
relacorilant
1
phenoxodiol
1
pembrolizumab
1
oregovomab
1
olaparib
1
nintedanib
1
lobaplatin
1
lanreotide
1
epothilone B
1
atezolizumab
1
Trabectedin
1
Topotecan
1
Therapeutics
1
Surgical Procedures, Operative
1
Saline Solution
1
Leucovorin
1
Letrozole
1
Laparotomy
1
Laparoscopy
1
LAIF 900
1
Hypericum extract LI 160
1
Glucose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Peritoneal Neoplasms
×
Bevacizumab
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts
NCT03038100
2023-02-17
IMagyn050
Hoffmann-La Roche
Phase 3
Completed
1,301 enrolled
22 charts
NCT01462890
2022-07-20
BOOST
AGO Study Group
Phase 3
Completed
927 enrolled